|
2011 AWARDS
NEW GRANT
Variable Expression of Argininosuccinate Synthetase Protein and
Correlation with Novel Therapeutic ADI-PEG20 in Osteosarcoma
Richard Gorlick, M.D.- The Childrens's Hospital at Montefiore, Bronx, New York
The amino acid arginine is involved in protein synthesis and tumor
metabolism and is essential for the growth of human cancer cells.
Pegylated arginine deaminase (ADI-PEG20) is a novel therapy that
lowers extracellular arginine levels and has shown evidence of
clinical efficacy and low toxicity in patients with tumors lacking
argininosuccinate synthetase (ASSl) protein expression. Previous
studies have demonstrated the effectiveness of ADI-PEG20 in cancer
cell lines with diminished or absent ASS1 protein including melanoma
and hepatocellular carcinoma. Breast cancer and lung cancer cell
lines, both of which frequently maintain strongly positive ASS1
protein expression, continued to proliferate in the presence of
ADI-PEG20. ADI-PEG20 sensitivity has not been previously evaluated in
osteosarcoma.
CONTINUED FUNDING
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial
Sloan Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of federally
supported cancer genomics efforts such as The Cancer Genome Atlas. Our
study will
comprehensively screen the genome of both pediatric and adult Osteosarcomas for
cancer causing mutations. Genomic technologies have advanced rapidly
in recent years,
making it possible to completely screen all genes in a given tumor
sample for mutations.
Screening of even a small number of samples of a given cancer type can
yield important discoveries.
The uniqueness of this study is that the analysis is coming from
patients tumors at different
stages of their disease i.e. not only biopsies.
CONTINUED FUNDING
Awarded in 2010 The Swim Across America Foundation
of Nassau and Suffolk
“Stacey Leondis Fellowship at The Children’s’
Hospital at Montefiore”, Bronx, New York.
This annual support is given
in Stacey's memory for a fellowship to further the osteosarcoma
research effort in the laboratory of Dr. Richard Gorlick.
2010 AWARDS
NEW
GRANT
The Osteosarcoma Genome Project
Marc Ladanyi, M.D., Paul Meyers, M.D. John Healey, M.D. - Memorial
Sloan Kettering Cancer Center-New York, New York
Awarded in 2010: Osteosarcoma is not currently a focus of
federally supported cancer genomics efforts such as The Cancer Genome
Atlas or the TARGET initiative. Our study will comprehensively screen
the genome of both pediatric and adult Osteosarcomas for cancer causing
mutations. Genomic technologies have advanced rapidly in recent years,
making it possible to completely screen all genes in a given tumor
sample for mutations. Screening of even a small number of samples of a
given cancer type can yield important discoveries.
CONTINUED FUNDING
awarded
in 2010
The
Swim Across America
Foundation of Nassau and Suffolk
-“Stacey
Leondis Fellowship at The Children’s’ Hospital at Montefiore”,
Bronx, New York. This annual support is given in Stacey's memory for a
fellowship to further the osteosarcoma research effort in the laboratory
of Dr. Richard Gorlick.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New
York, New York
CONTINUED FUNDING
awarded in 2009: This study of IGF-1R (insulin like growth factor), a
highly active molecular pathway for osteosarcoma continues.
CONTINUING
awarded in 2009: We have co sponsored with the
Stavros Niarchos Foundation
a study being performed by Dr. Jennifer Perry at the Dana Farber Cancer
Institute, Boston, Massachusetts. Her experiments will attempt to
identify new pathways that are required for the viability and
proliferation of p53/pRb-null osteosarcoma cells. CONTINUING
awarded in 2009: This study is being performed by Dr. Erik Sampson at
The University of Rochester, Rochester, New York. Dr. Sampson’s study is
a preclinical evaluation of the c-Met inhibitor MK-8033 for the
treatment of human osteosarcoma.
2009 AWARDS
NEW GRANT
The
Swim Across America Foundation of Nassau and Suffolk
has created the
“Stacey Leondis Fellowship at The Children’s’ Hospital at Montefiore”,
Bronx, New York. This annual support will be given to the osteosarcoma
research laboratory of Dr. Richard Gorlick in Stacey’s memory.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial Sloan Kettering Cancer Center-New
York, New York
CONTINUED FUNDING
awarded in 2009: This study of IGF-1R (insulin like growth factor), a
highly active molecular pathway for osteosarcoma continues.
NEW GRANT awarded in 2009: We have co sponsored
with the
Stavros Niarchos Foundation a study being performed by Dr. Jennifer
Perry at the Dana Farber Cancer Institute, Boston, Massachusetts. Her
experiments will attempt to identify new pathways that are required for
the viability and proliferation of p53/pRb-null osteosarcoma cells.
NEW GRANT awarded in 2009: This study is being
performed by Dr. Erik Sampson at The University of Rochester, Rochester,
New York. Dr. Sampson’s study is a preclinical evaluation of the c-Met
inhibitor MK-8033 for the treatment of human osteosarcoma.
2008
AWARDS
CONTINUED FUNDING
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial
Sloan Kettering Cancer Center-New York, New York
awarded in 2008: We have been co-funding with the
Swim
Across America Foundation of Nassau and Suffolk for the past 3 years, a
study of IGF-1R (insulin like growth factor), a highly active molecular
pathway for osteosarcoma. We are very pleased to state that this study
provided much of the basic science research needed for the initiation of
a Phase II clinical trial of IGF-1R targeted therapy in osteosarcoma
patients. A Phase III trial is currently in development based on
promising results from the Phase II study. This is the first time that a
targeted therapy for osteosarcoma will enter a Phase III clinical trial!
NEW GRANT
awarded in 2008: We have co-sponsored with the
Liddy Shriver
Sarcoma Initiative a study at The University of Texas -MD Anderson
Cancer Center, Houston, Texas for Dr. Nadezhda Koshkina's study of the
role of CIP4 in osteosarcoma metastases.
NEW GRANT
awarded in 2008:
We have co sponsored with the
Stavros Niarchos Foundation
a study being performed by Dr. Anders Kolb at the AI Dupont Hospital for Children. His experiments will examine the effect of
a monoclonal antibody against IGF-1R in a xenograft model. This work
seeks to identify the potential downstream targets in responsive
tumors. Dr. Kolb proposes to use gene array in a series of responsive
and non-responsive tumors to determine the targets involved. This will
allow optimization of patient selection for this therapy as well as the
design of more effective treatment combinations.
2007
AWARDS Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
Dr. Alex Chou- Pediatrics-Memorial
Sloan Kettering Cancer Center-New York, New York
NEW GRANT
awarded in 2007: The study is attempting to define which pathway(s) is used by osteosarcoma. Additionally it will analyze and
prioritize which small molecule pathway inhibitor(s) could be used to
treat osteosarcoma.
Peter Menges - Foster Board Member
Robert Panariello - Professional
Athletic Performance Center, Garden City, New York
CONTINUED FUNDING
in 2007 for the physical conditioning and positive
self image program designed especially for children upon completion of
or during treatment for any pediatric cancer. Mark Weinblatt, MD,
Pediatric Oncology Medical Director at Winthrop-University Hospital's
Cancer Center for Kids referred the first two groups of participants in
2006.
CLICK HERE for News Article:
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue
Zhang-PHD- Applied Math and Statistics
Renyuan Luo-Graduate Student-Applied Math and Statistics
SUNY at
Stony Brook-New York
CONTINUED FUNDING
in 2007 for the development of a
"translational tool" (computer program) that can predict response to chemotherapy, for
Osteosarcoma, prior to treatment using microarray genetic signatures.
2006 AWARDS Chand Khanna- DVM, PhD, National
Cancer Institute, Bethesda, Maryland -
Research & Tumor Metastasis Section - Pediatric Oncology Branch
NEW GRANT
for the testing of a "targeted" (limited toxicity) agent for osteosarcoma in an animal study for the National Institute of Health -
Comparative Oncology - Pediatrics.
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
NEW GRANT
awarded
for the upgrade of the genetic sequencer at the pediatric sarcoma lab.
This upgrade is a four fold improvement in the labs SAGE sequencing
capabilities.
CLICK HERE for Thank You Letter
Peter Menges - Foster Board Member - Garden City, New York
NEW GRANT
in 2006 for the "trial" of a physical conditioning and positive self
image program for children upon completion of therapy, of any pediatric
cancer.
CLICK HERE for News Article
Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and
Statistics
CONTINUED FUNDING
in 2006
to Dr. Zhu for the development of
a mathematical algorithm for osteosarcoma. This program will attempt to
correlate SAGE data to DNA microarray data to patient status.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
All from SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2006 for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma,
prior to treatment using microarray genetic signatures.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2006 for the analysis of metastatic osteosarcoma datasets using
microarray and SAGE signatures.
2005 AWARDS
Dr. Richard Gorlick- Montefiore Children's Hospital, Bronx- New York-
Osteosarcoma Research Laboratory
NEW GRANT
awarded
for the compiling of microarray and SAGE datasets for metastatic
Osteosarcoma.
Wei Zhu, PHD, SUNY at Stony Brook-New York, New York-Applied Math and
Statistics
CONTINUED FUNDING
in 2005
to Dr. Zhu for the development of
a mathematical algorithm for osteosarcoma. This program will attempt to
correlate SAGE data to DNA microarray data to patient status.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Neophytos Neophytou , Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook-New York
CONTINUED FUNDING
in 2005 for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma,
prior to treatment using microarray genetic signatures.
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
SUNY at Stony Brook-New York
NEW GRANT
awarded
for the analysis of metastatic osteosarcoma datasets using
microarray and SAGE signatures.
2004 AWARDS
Professor Wei Zhu, PHD, New York-Applied Math and Statistics
Yue Zhang-PHD- Applied Math and Statistics
Neophytos Neophytou ,
Ph.D. Student, Department of Computer Science
All from SUNY at Stony Brook
NEW GRANT
awarded for the development of a “translational tool”
(computer program) that can predict response to chemotherapy, for Osteosarcoma, prior to treatment using microarray genetic
signatures.
Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
CONTINUED FUNDING
in 2004 to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data
to DNA microarray data to patient status.
PHOTO UPDATE! -- Wei Zhu
Group Click here to view the photo...
2003 AWARD
Wei Zhu, PHD, SUNY at Stony Brook, New York-Applied Math and Statistics
NEW GRANT
awarded to Dr. Zhu for the development of a mathematical algorithm for osteosarcoma. This program will attempt to correlate SAGE data
to DNA microarray data to patient status.
PHOTO UPDATE! -- Wei Zhu, PHD - SUNY at Stony Brook Click here to view the photo...
2002 AWARD
Dr. Richard Gorlick of The Sloan Kettering Memorial Cancer Center,
New York-The Pediatric Sarcoma Research Laboratory
NEW GRANT
awarded to Dr. Gorlick for the purchase of an Applied Biosystem Inc.-ABI
Prism 3100 Genetic Analyzer. This new device will enable the
laboratory to expedite and further analyze different genetic
expressions and possible targets for additional research.
NEWS UPDATE! -- Dr. Gorlick reports on findings! Click here to view his letter...
|
